Clinical Trials Logo

Clinical Trial Summary

The main aim of this study is to: - evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of AMG 757 for Part 1 only - evaluate anti-tumor activity of AMG 757 as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05060016
Study type Interventional
Source Amgen
Contact Amgen Call Center
Phone 866-572-6436
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date November 29, 2021
Completion date August 15, 2024